Autologous, lentivirus-modified, T-rapa cell "micropharmacies" for lysosomal storage disorders.
Ontology highlight
ABSTRACT: T cells are the current choice for many cell therapy applications. They are relatively easy to access, expand in culture, and genetically modify. Rapamycin-conditioning ex vivo reprograms T cells, increasing their memory properties and capacity for survival, while reducing inflammatory potential and the amount of preparative conditioning required for engraftment. Rapamycin-conditioned T cells have been tested in patients and deemed to be safe to administer in numerous settings, with reduced occurrence of infusion-related adverse events. We demonstrate that ex vivo lentivirus-modified, rapamycin-conditioned CD4+ T cells can also act as next-generation cellular delivery vehicles-that is, "micropharmacies"-to disseminate corrective enzymes for multiple lysosomal storage disorders.
SUBMITTER: Nagree MS
PROVIDER: S-EPMC8988206 | biostudies-literature | 2022 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA